COLUMBUS, Ohio — Jeffrey Patrick, PharmD, has been named director of the Drug Development Institute (DDI) at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), effective Feb. 13, 2017.
Created by the OSUCCC – James and with the help of seven Ohio State colleges and the university’s technology commercialization office, the DDI helps accelerate cancer drug development through strategic partnerships within the global pharmaceutical and research/development industries. DDI has cataloged 30 novel anticancer agents developed at Ohio State and is currently working to advance the most promising toward phase 1 human testing by seeking investigational new drug applications by 2020.
“Over the past five years, we have quietly built a pipeline for advancing early stage research to ensure the most promising new cancer therapy approaches do not languish in university laboratories,” says Michael Caligiuri, MD, director of the OSUCCC and chief executive officer of the James Cancer Hospital and Solove Research Institute. “Dr. Patrick brings deep knowledge and experience from the pharmaceutical industry that will help take our cancer program’s drug development efforts to the next level, and ultimately create new therapeutics for cancer patients.”
Dr. Patrick joins the OSUCCC – James from New Haven Pharmaceuticals in Connecticut, where he served as chief scientific officer. In this role, he was responsible for leading development and implementation of scientific strategy for company products and leading the design and implementation of preclinical and clinical trials.
Patrick has nearly 20 years of experience in the pharmaceutical industry, serving as in past roles as global vice president of professional affairs at Mallinckrodt Pharmaceuticals, Inc.; director of medical science liaisons at Dyax Corp.; field director for medical sciences at Myogen/Gilead Sciences; senior medical science liaison at Actelion Pharmaceuticals US Inc.; and medical science liaison for Sanofi-Synthelabo Inc.
Prior to pursuing a career in research and development, Patrick was an ambulatory care clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy, where he earned his doctorate in pharmacy. He also completed the Wharton School of Business Pharmaceutical Executive Program. In his new role, Dr. Patrick will report to Jeff Walker, chief operating officer and senior executive director for administration for the OSUCCC – James.